Policy & Regulation
BioPharmX Corporation reports fiscal quarter ended 31 July 2019 financial results
10 September 2019 -

BioPharmX Corporation (NYSE American: BPMX), a specialty pharmaceutical company focused on developing innovative medical dermatology products, reported yesterday its financial results for the fiscal quarter ended 31 July 2019.

The company reported total operating expenses at USD2.7m for the second fiscal quarter ended 31 July 2019 against the total operating expenses of USD4.5m in the year-ago period.

The firm posted net loss for the fiscal quarter ended 31 July 2019 at USD2.6m compared with a net loss of USD4.4m in the same period in 2018.

'This was an important quarter for BioPharmX to position our late-stage product candidates for continued success. We were extremely pleased to deliver positive Phase 2b trial results for BPX-04 as well as to secure additional patent protection for the underlying technology,' said Dr Tierney, BioPharmX CEO.

Login
Username:

Password:


Related Headlines